Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant Pharma (JPL), a company incorporated under the laws of Singapore, has successfully priced its rated unsecured bonds at 6.00% per annum issued at par for $200 million maturing in March, 2024.
S&P Global Ratings (S&P) has affirmed ‘BB-/positive’ rating and Fitch Ratings (Fitch) has affirmed ‘BB-/Stable’ rating for JPL. The Notes have been rated ‘BB-’ by S&P and ‘BB’ by Fitch.
The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
